Coherus BioSciences (CHRS) Reports In-Line Q1 EPS
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.29 +4.88%
EPS Growth %: +39.4%
Financial Fact:
Gross profit: 261.73M
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: +39.4%
Financial Fact:
Gross profit: 261.73M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q1 EPS of ($0.25), in-line with the analyst estimate of ($0.25). Revenue for the quarter came in at $12.31 million versus the consensus estimate of $14.43 million.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Downgrades Nucor (NUE) to Hold, 'Guides Conservative Earnings Yet Again'
- Li Auto Inc. (LI) call put ratio 1.1 calls to 1 put with a focus on September 25 weekly 12.5 puts
- Alibaba (BABA) call put ratio 2.4 calls to 1 put as share price up 3% into President Donald Trump and Chinese President Xi Jinping's summit
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
